Abstract

Seven viruses cause at least 15% of the total cancer burden. Viral cancers have been described as the “low-hanging fruit” that can be potentially prevented or treated by new vaccines that would alter the course of global human cancer. Kaposi sarcoma herpesvirus (KSHV or HHV8) is the sole cause of Kaposi sarcoma, which primarily afflicts resource-poor and socially marginalized populations. This review summarizes a recent NIH-sponsored workshop’s findings on the epidemiology and biology of KSHV as an overlooked but potentially vaccine-preventable infection. The unique epidemiology of this virus provides opportunities to prevent its cancers if an effective, inexpensive, and well-tolerated vaccine can be developed and delivered.

Details

Title
KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine
Author
Casper, Corey 1   VIAFID ORCID Logo  ; Corey, Lawrence 2   VIAFID ORCID Logo  ; Cohen, Jeffrey I. 3 ; Damania, Blossom 4 ; Gershon, Anne A. 5   VIAFID ORCID Logo  ; Kaslow, David C. 6   VIAFID ORCID Logo  ; Krug, Laurie T. 7   VIAFID ORCID Logo  ; Martin, Jeffrey 8 ; Mbulaiteye, Sam M. 9   VIAFID ORCID Logo  ; Mocarski, Edward S. 10 ; Moore, Patrick S. 11   VIAFID ORCID Logo  ; Ogembo, Javier Gordon 12   VIAFID ORCID Logo  ; Phipps, Warren 13 ; Whitby, Denise 14 ; Wood, Charles 15 

1  Infectious Disease Research Institute, Seattle, USA (GRID:grid.53959.33) (ISNI:0000 0004 1794 8076) 
2  Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622) 
3  National Institutes of Health, Laboratory of Infectious Diseases, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165) 
4  The University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center & Department of Microbiology and Immunology, Chapel Hill, US (GRID:grid.10698.36) (ISNI:0000000122483208) 
5  Columbia University, Department of Pediatrics, Vagelos College of Physicians & Surgeons, New York, US (GRID:grid.21729.3f) (ISNI:0000000419368729) 
6  PATH Essential Medicines, PATH, Seattle, USA (GRID:grid.415269.d) (ISNI:0000 0000 8940 7771) 
7  National Cancer Institute, HIV and AIDS Malignancy Branch, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075) 
8  University of California, Department of Epidemiology and Biostatistics, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
9  HHS, Division of Cancer Epidemiology & Genetics, National Cancer Institute, NIH, Bethesda, USA (GRID:grid.27235.31) 
10  Emory University, Emory Vaccine Center, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502) 
11  University of Pittsburgh, Cancer Virology Program, Hillman Cancer Center, Pittsburgh, USA (GRID:grid.21925.3d) (ISNI:0000 0004 1936 9000) 
12  Beckman Research Institute of City of Hope, Department of Immuno-Oncology, Duarte, USA (GRID:grid.410425.6) (ISNI:0000 0004 0421 8357) 
13  University of Washington, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Department of Medicine, Division of Allergy and Infectious Diseases, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657) 
14  Frederick National Laboratory for Cancer Research, AIDS and Cancer Virus Program, Frederick, USA (GRID:grid.418021.e) (ISNI:0000 0004 0535 8394) 
15  Louisiana State University Health Sciences Center, Department of Interdisciplinary Oncology, New Orleans, USA (GRID:grid.279863.1) (ISNI:0000 0000 8954 1233) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20590105
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41541-022-00535-4
ProQuest document ID
2715917225
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.